VNRX
VolitionRX Ltd (VNRX)
Healthcare • NYSE MKT • $2.25-7.02%
- Symbol
- VNRX
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $2.25
- Daily Change
- -7.02%
- Market Cap
- $18.20M
- Trailing P/E
- N/A
- Forward P/E
- 0.47
- 52W High
- $18.80
- 52W Low
- $2.17
- Analyst Target
- $29.21
- Dividend Yield
- N/A
- Beta
- 1.03
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Company websiteResearch VNRX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.